期刊
NMR IN BIOMEDICINE
卷 23, 期 2, 页码 123-132出版社
WILEY
DOI: 10.1002/nbm.1428
关键词
H-1 NMR spectroscopy; biomarkers; cerebrospinal fluid and serum; diagnosis; neurology; metabolomics; metabolic profiling
资金
- Vera Down
- Clark & McMaster Awards
- British Medical Association, UK
- The West Midlands Neuroscience Teaching and Research Fund, UK
- Alexandra Sinclair is a Brain Trust Entry/Exit Scholar (Institute of Neurology, London, UK)
- Ipsen Research Fellow (London, UK)
- MRC Clinical Training Fellow (London, UK)
- Birmingham Eye Foundation [257549]
- NERC [NER/J/S/2002/00618]
- Medical Research Council [G0601430] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish
- Natural Environment Research Council [NER/J/S/2002/00618] Funding Source: researchfish
- MRC [G0601430] Funding Source: UKRI
We sought to evaluate the diagnostic accuracy of metabolomic biomarker profiles in neurological conditions (idiopathic intracranial hypertension (IIH), multiple sclerosis (MS) and cerebrovascular disease (CVD) compared to controls with either no neurological disease or mixed neurological diseases). Spectra of CSF (n = 87) and serum (n = 72) were acquired using H-1 NMR spectroscopy. Multivariate pattern recognition analysis was used to identify disease-specific metabolite biomarker profiles. The metabolite profiles were then used to predict the diagnosis of a second cohort of patients (n = 25). CSF metabolite profiles were able to predict diagnosis with a sensitivity and specificity of 80% for both IIH and MS. The CVD serum metabolite profile was 75% sensitive and specific. On analysing the second patient cohort, the established metabolite biomarker profiles generated from the first cohort showed moderate ability to segregate patients with IIH and MS (sensitivity:specificity of 63:75% and 67:75%, respectively). These findings suggest that NMR spectroscopic metabolic profiling of CSF and serum can identify differences between IIH, MS, CVD and mixed neurological diseases. Metabolomics may, therefore, have the potential to be developed into a clinically useful diagnostic tool. The identification of disease-unique metabolites may also impart information on disease pathology. Copyright (C) 2009 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据